Ray Dirks
Contributor since: 2012
Latest Articles
All Eyes On Local: Monetizing The Multibillion-Dollar Online And Mobile Consumer Ad Market
Local Corporation Dominates Local Mobile And Online Advertising With Record Quarter
Cel-Sci's Successful Safety Review Not Yet Factored Into Valuation
Local Corporation's Valuation Next To Peers Makes It An Obvious Opportunity
Medgenics' Bulging Pipeline Of Blockbuster Indications Takes On Big Pharma's Harmful Drugs
Broad Markets, Big Money, Harmful Drugs - Pluristem Takes On The Blockbusters
Pluristem Therapeutics Shoots From The Hip, Moving Toward The Sports Medicine And Muscle Regeneration Markets
Pluristem's Cell Therapy For Bone Marrow A Blockbuster In The Making
Well Funded Pluristem Adds Another Blockbuster Indication To Potent Pipeline
Pluristem Therapeutics' Answer To Big Pharma's Question: What Do We Do Now?
Medgenics Continues To Move Rapidly In The Right Direction
Orphan Drug Approval For Medgenics' Hepatitis Therapy Makes It Big Pharma Target
Medgenics Moving In Record Time
Pluristem Therapeutics' New Indication May Boost Company Valuation
Investors Waking Up To Pluristem's Developments
Game Changer: Medgenics' FDA Fast Track Application For Hepatitis
Pluristem Takes A Huge Step For The Entire Cell Therapy Sector
Cel-Sci Shares Still Undervalued: How Does This Make Sense?
Pluristem Therapeutics: Plant Scale-Up, Outstanding Heart Tissue Data Signal Buy Opportunity
Will Medgenics Become The Next Hepatitis-C Take Over Candidate?
Backed By Investors Behind Twitter, Yelp And eBay, Emerging Tech Company Starting To Ring Up Deals
Medgenics' Disruptive Biotechnology Is One To Watch